In a pooled analysis of different cohorts of patients with KRAS-mutated NSCLC, including 44 patients treated in the CheckMate-057 study, Skoulidis et al. showed that LKB1-deficient NSCLC patients treated with PD-1 axis inhibitors had significantly shorter PFS and OS when compared with patients with LKB1-proficient tumors. This evidence concerns the gene KRAS and non-small cell lung carcinoma.